Semaglutide Weight Management and Cardiovascular Risk Reduction
Once-weekly insulin icodec appeared to be effective and to have
a safe profile in the phase 3 ONWARDS programme
ONWARDS 1
BASAL INITIATION
522
ONWARDS 3
BASAL INITIATION
ONWARDS 5
BASAL INITIATION
ONWARDS 2
BASAL SWITCH
ONWARDS 4
BASAL/BOLUS SWITCH
26
ONWARDS 6
BASAL/BOLUS SWITCH
262
Trial duration (weeks)
26
52
26
(Full trial: 78 weeks)
Baseline HbA1c
(%)
Non-inferiority confirmed
8.5%
✓
8.5%
✓
8.9%
8.1%
✓
8.3%
(Full trial: 52 weeks)
7.6%
✓
Superiority confirmed
Estimated change from
baseline in HbA1c (%)
-0.47% -0.51%
-0.71%
-0.93%*
-1.16% -1.18%
-1.55%*-1.35%
*-1.36%
-1.31%
19.93
-1.57%*
-1.68%*
*
10.37
Hypoglycaemia event
0.30
0.16
rates¹
0.31 0.15
5.64 5.62
0.19 0.14
0.73 0.27
Insulin-treated type 2 diabetes
Type 1 diabetes
Once-daily insulin degludec
Once-daily basal insulins
Insulin-naïve type 2 diabetes
In people with type 2 diabetes: No statistical difference in estimated hypoglycaemia events
Once-weekly insulin icodec
Once-daily insulin glargine U100
*Statistically significant. 1 Severe or clinically significant hypoglycaemia events (blood glucose <3 mmol/L) per patient year, included for end of trial/end main phase in-trial. 2 Duration refers to trial main phase.
ONWARDS 1: QW insulin icodec vs QD insulin glargine U100 both with non-insulin anti-diabetic treatment in insulin-naïve people with T2D; ONWARDS 2: QW insulin icodec vs QD insulin degludec in people with T2D switching from a QD insulin; ONWARDS 3: QW
insulin icodec vs QD insulin degludec in insulin-naïve people with T2D; ONWARDS 4: QW insulin icodec vs QD insulin degludec both with mealtime insulin in people with T2D treated with basal and bolus insulin; ONWARDS 5: QW insulin icodec vs QD basal insulin
with an app providing dosing recommendation in insulin-naïve people with T2D; ONWARDS 6: QW insulin icodec vs QD insulin degludec both with mealtime insulin in people with T1D
T1D: Type 1 diabetes; T2D: Type 2 diabetes. Note: Overview refer to primary end-points in main phases of trialsView entire presentation